Kintara Therapeutics (STU:3DMA) Other Long-Term Liabilities : €0.17 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics Other Long-Term Liabilities?

Kintara Therapeutics's other long-term liabilities for the quarter that ended in Mar. 2024 was €0.17 Mil.

Kintara Therapeutics's quarterly other long-term liabilities increased from Sep. 2023 (€0.16 Mil) to Dec. 2023 (€0.16 Mil) and increased from Dec. 2023 (€0.16 Mil) to Mar. 2024 (€0.17 Mil).

Kintara Therapeutics's annual other long-term liabilities increased from Jun. 2021 (€0.15 Mil) to Jun. 2022 (€0.15 Mil) but then declined from Jun. 2022 (€0.15 Mil) to Jun. 2023 (€0.15 Mil).

Kintara Therapeutics Other Long-Term Liabilities Historical Data

The historical data trend for Kintara Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Other Long-Term Liabilities Chart

Kintara Therapeutics Annual Data

Trend

Dec13

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Kintara Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Kintara Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Kintara Therapeutics Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintara Therapeutics (STU:3DMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (STU:3DMA) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

KTRA:USA

Address

9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121

Website

https://www.kintara.com

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics (STU:3DMA) Headlines

No Headlines